Views & Analysis | Perspectives on pharma industry issues

Patients

pharmaphorum podcast Episode 256, Dean Erhardt, D2 Solutions

Providing patient access to new therapies, with Dean Erhardt

Dean Erhardt, founder of D2 Solutions, discusses patient access today versus the state of patient access tomorrow.

Patients

Pharmacist with patient and prescription

From access to advocacy: Turning patients into brand champio...

Done right, DTP is not just filling scripts. It is building loyalty that turns satisfied patients into lifelong advocates.

Sales & Marketing

Sponsored

Solution Spotlight: Own The Moments That Matter Most

Medscape Contextual Moments is a suite of integrated opportunities that deliver messaging alongside independent Medscape trusted editorial content.

R&D

HCP takes blood pressure of pregnant woman

DiaMedica’s novel biologic basal dilator: Bringing hope to p...

pharmaphorum spoke with DiaMedica’s CEO, Rick Pauls, about the company's efforts in preeclampsia, early-onset preeclampsia, and ischaemic stroke.

Digital

Controlling AI hallucinations: Building evidence-based trust...

When it comes to GenAI, industry must demand evidence-grounded systems that prioritise verifiable clinical data and rigorous human oversight.

R&D

Brighter times ahead for biotech in 2024?

The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies.

R&D

A clearer harmony and attractiveness for EU Clinical Trials ...

EU Clinical Trials Regulation (EU CTR) has been a hot topic for a little while now.

R&D

Changing Faces: Pharma and biotech hires from January 2024

It’s a new year, so we’re kicking it off with the relaunch of Changing Faces after we lost the thread a bit last year.

Sales & Marketing

Sponsored

Solution Spotlight: Own The Moments That Matter Most

Medscape Contextual Moments is a suite of integrated opportunities that deliver messaging alongside independent Medscape trusted editorial content.

Sales & Marketing

Sponsored

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

Digital

Controlling AI hallucinations: Building evidence-based trust...

When it comes to GenAI, industry must demand evidence-grounded systems that prioritise verifiable clinical data and rigorous human oversight.

Digital

Changing Faces: Digital and supplier, March 2026

Digital health companies, clinical trial technology providers, and life sciences suppliers continued to invest in senior leadership in March.

Market Access

Capital discipline in biotech: Building enduring companies w...

Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.

Market Access

Metrics discussion around boardroom table

Highlights from the UK’s December 2025 VPAG metrics

Leela Barham looked at the latest metrics used to monitor the UK’s voluntary pricing scheme.

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Patients

R&D

DiaMedica’s novel biologic basal dilator: Bringing hope to p...

pharmaphorum spoke with DiaMedica’s CEO, Rick Pauls, about the company's efforts in preeclampsia, early-onset preeclampsia, and ischaemic stroke.

R&D

Sponsored

12 Questions with Faruk Uzman

Find out more about Faruk Uzman, VP EMEA at Boston Scientific, in a new 12 Questions With.

R&D

The conflict in the Middle East is exposing dangerous prepar...

If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.

Providing patient access to new therapies, with Dean Erhardt

From access to advocacy: Turning patients into brand champio...

Solution Spotlight: Own The Moments That Matter Most

DiaMedica’s novel biologic basal dilator: Bringing hope to p...

Controlling AI hallucinations: Building evidence-based trust...

Brighter times ahead for biotech in 2024?

A clearer harmony and attractiveness for EU Clinical Trials ...

Changing Faces: Pharma and biotech hires from January 2024

Solution Spotlight: Own The Moments That Matter Most

Pushing through barriers to commercial launch success, with ...

Controlling AI hallucinations: Building evidence-based trust...

Changing Faces: Digital and supplier, March 2026

Capital discipline in biotech: Building enduring companies w...

Highlights from the UK’s December 2025 VPAG metrics

From promise to practice: What must happen next for genetic ...

LSX2026: Addressing adult eye cancer, with Roi Raz

From preclinical toxicology to clinical safety: The path for...

Providing patient access to new therapies, with Dean Erhardt

From access to advocacy: Turning patients into brand champio...

Rewriting the MASLD playbook

DiaMedica’s novel biologic basal dilator: Bringing hope to p...

12 Questions with Faruk Uzman

The conflict in the Middle East is exposing dangerous prepar...

Providing patient access to new therapies, with Dean Erhardt

Using AI-driven synthetic personas to take your insights fur...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks